Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: A randomized and prospective study

Urology

Volumn 67, Issue 5, 2006, Pages 1038-1042

  Inal, Tansel ^a   Tokatli, Zafer ^a   Akand, Murat ^a   Özdiler, Erol ^a   Yaman, Önder ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; HYPOCHOLESTEROLEMIC AGENT; ORAL ANTIDIABETIC AGENT; PAPAVERINE; PARACETAMOL; RECOMBINANT ALPHA2B INTERFERON; ALPHA2B INTERFERON; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTHRALGIA; ARTICLE; CALCIFICATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOPPLER ECHOGRAPHY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FEVER; FLU LIKE SYNDROME; FOLLOW UP; GENITAL PAIN; HUMAN; HYPERTENSION; MALE; MALE SEXUAL DYSFUNCTION; MYALGIA; PATIENT ASSESSMENT; PEYRONIE DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEXUAL INTERCOURSE; STATISTICAL SIGNIFICANCE; COMPARATIVE STUDY; DRUG COMBINATION; IMPOTENCE; INTRALESIONAL DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PAIN; PENIS; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG THERAPY, COMBINATION; HUMANS; IMPOTENCE; INJECTIONS, INTRALESIONAL; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PAIN; PENILE INDURATION; PENIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VITAMIN E;

EID: 33646842493     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2005.11.005     Document Type: Article

References (29)

1. Schwarzer U., Sommer F., Klotz T., et al. The prevalence of Peyronie's disease. results of a large survey. BJU Int 88 (2001) 727-730
2. Chiang P.H., Chiang C.P., Sen M.R., et al. Study of the changes in collagen of the tunica albuginea in venogenic impotence and Peyronie's disease. Eur Urol 21 (1992) 48-51
3. Briganti A., Salonia A., Deho F., et al. Peyronie's disease. a review. Curr Opin Urol 13 (2003) 417-422
4. Dang G., Matern R., Bivalacqua T.J., et al. Intralesional interferon-α 2b injections for the treatment of Peyronie's disease. South Med J 97 (2004) 42-46
5. Benson Jr. R.C., Knoll L.D., and Furlow W.L. Interferon-α 2b in the treatment of Peyronie's disease. J Urol 145 suppl (1991) 1342A-1347A
6. Wegner H.E.H., Andresen R., Knispel H., et al. Local interferon-α 2b is not an effective treatment in early-stage Peyronie's disease. Eur Urol 32 (1997) 190-193
7. Brake M., Loertzer H., Horsch R., et al. Treatment of Peyronie's disease with local interferon-α 2b. BJU Int 87 (2001) 654-657
8. Judge J.S., and Wisniewski Z.S. Intralesional interferon in the treatment of Peyronie's disease. a pilot study. Br J Urol 79 (1997) 40-42
9. Ahuja S., Bivalacqua T.J., Case J., et al. A pilot study demonstrating clinical benefit from intralesional interferon-α 2b in the treatment of Peyronie's disease. J Androl 20 (1999) 444-448
10. Prieto Castro R.M., Leva Vallejo M.E., Reguiero Lopez J.C., et al. Combined treatment with vitamin E and colchicines in the early stages of Peyronie's disease. BJU Int 91 (2003) 522-524
11. Levine L.A., Merrick P.E., and Lee R.C. Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol 151 (1994) 1522-1524
12. Devine Jr. C.J., Somers K.D., Jordan G.H., et al. Proposal. trauma as the cause of the Peyronie's lesion. J Urol 157 (1997) 285-290
13. Hellstrom W.J.G., and Bivalacqua T.J. Peyronie's disease. etiology, medical, and surgical therapy. J Androl 21 (2000) 347-354
14. Moreland R.B., and Nehra A. Pathophysiology of Peyronie's disease. Int J Impot Res 14 (2002) 406-410
15. Somers K.D., and Dawson D.M. Fibrin deposition in Peyronie's disease plaque. J Urol 157 (1997) 311-315
16. Pryor J.P., and Ralph D.J. Clinical presentation of Peyronie's disease. Int J Impot Res 14 (2002) 414-417
17. Gholami S.S., Gonzalez-Cadavid N., Lin C.S., et al. Peyronie's disease. a review. J Urol 169 (2003) 1234-1241
18. Davis C.J. The microscopic pathology of Peyronie's disease. J Urol 157 (1997) 282-284
19. Brock G., Hsu G.L., Nunes L., et al. The anatomy of the tunica albuginea in the normal penis and Peyronie's disease. J Urol 157 (1997) 276-281
20. Vahlensieck Jr. W.K.G., Schaefer H.E., and Westenfelder M. Penile ossification and acquired penile deviation. Eur Urol 27 (1995) 252-256
21. Devine C.J., Jordan G.H., and Schlossberg S.M. Peyronie's disease. In: Walsh P.C., Retik A.B., Stamey T.A., et al. (Eds). Campbell's Urology vol 6 (1992), WB Saunders, Philadelphia 3011-3022
22. Ludwig G. Evaluation of conservative therapeutic approaches to Peyronie's disease (fibrotic induration of the penis). Urol Int 47 (1991) 236-239
23. Duncan M.R., Berman B., and Nseyo U.O. Resolution of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferon-alpha, -beta, and -gamma. Scand J Urol Nephrol 25 (1991) 89-94
24. Ahuja S.K., Case J., Vincent M., et al. Intralesional injection of alpha-interferon-2b in the treatment of Peyronie's disease. J Urol 159 suppl (1998) 117A-123A
25. Scardino P.L., and Scott W.W. The use of tocopherols in the treatment of Peyronie's disease. Ann NY Acad Sci 52 (1949) 390-401
26. Chesney J. Peyronie's disease. Br J Urol 47 (1975) 209-218
27. Scott W.W., and Scardino P.L. New concept in the treatment of Peyronie's disease. South Med J 41 (1947) 173-177
28. Pryor J.P., and Farrell C.R. Controlled clinical trial of vitamin E in Peyronie's disease. Prog Reprod Biol Med 9 (1983) 41-45
29. Gelbard M.K., Dorey F., and James K. The natural history of Peyronie's disease. J Urol 144 (1990) 1376-1379